A Phase 2 interventional study of HRS-7058 + SHR-1316 and HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy in Advanced Malignant Tumour, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-7058 + SHR-1316
Drug: HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
Drug: HRS-7058 + Cetuximab
Drug: HRS-7058 + SHR-1826
Drug: HRS-7058 + SHR-1826 + SHR-1316
Drug: HRS-7058 + SHR-A1202
Drug: HRS-7058 + BP102
Drug: HRS-7058 + SHR-9839
Drug: HRS-7058 +SHR-A2102 +SHR-1316
Drug: HRS-7058 +SHR-9839(sc)+SHR-1316
Drug: HRS-7058 +SHR-1316 +BP102
Drug: HRS-7058 +SHR-A2102 +BP102
Drug: HRS-7058 +SHR-A2102 +SHR-1316 +BP102
Drug pages: HRS-7058 · Adebrelimab
HRS-7058 + SHR-1316
HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy
Drug pages: HRS-7058 · Cetuximab
HRS-7058 + Cetuximab
HRS-7058 + SHR-1826
Drug pages: HRS-7058 · SHR-1826 · Adebrelimab
HRS-7058 + SHR-1826 + SHR-1316
HRS-7058 + SHR-A1202
Drug page: BP102
HRS-7058 + BP102
HRS-7058 + SHR-9839
Drug pages: HRS-7058 · Notiretatug rezetecan · Adebrelimab
HRS-7058 +SHR-A2102 +SHR-1316
Drug pages: HRS-7058 · SHR-9839 · Adebrelimab
HRS-7058 +SHR-9839(sc)+SHR-1316
Drug page: BP102
HRS-7058 +SHR-1316 +BP102
Drug page: BP102
HRS-7058 +SHR-A2102 +BP102
Drug page: BP102
HRS-7058 +SHR-A2102 +SHR-1316 +BP102
Dose-limiting toxicity (DLT) (Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
Safety endpoints: adverse events (AE) (Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]
Phase II recommended dose (RP2D)(Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]
Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months
Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
Efficacy endpoints: overall survival (OS)(Dose Escalation and Dose Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months
Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months
Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months
Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion (Efficacy Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months
Efficacy endpoints: overall survival (OS) (Efficacy Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months
Safety endpoints: adverse events (AE)(Efficacy Expansion)
Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: HRS-7058 · Adebrelimab · Cetuximab · SHR-1826 · BP102 · Notiretatug rezetecan · SHR-9839
Shandong Suncadia Medicine Co., Ltd. →